Fosun Swings to Record 2025 Loss on Heavy Impairments as It Refocuses on Core Businesses

Fosun International ( (HK:0656) ) has shared an announcement.

Fosun International reported 2025 revenue of RMB173.4 billion, down from the prior year, with overseas operations contributing 54.7% of the total. The group posted a record loss attributable to shareholders of RMB23.4 billion and suspended its dividend, but maintained positive operating cash flow, a declining average cost of debt and stable external credit ratings.

Management attributed the loss largely to non‑cash impairment charges on historical and non‑core projects, including goodwill and intangible assets, rather than a deterioration of underlying operations, which remained resilient in core segments such as pharmaceuticals and insurance. The board framed the write‑downs as a strategic clean‑up to optimize the asset mix, exit weaker exposures such as challenged real estate investments, and sharpen focus on higher‑growth, innovation‑driven businesses, aiming to make Fosun a leaner and more sustainable group for investors and other stakeholders.

The most recent analyst rating on (HK:0656) stock is a Hold with a HK$4.00 price target. To see the full list of analyst forecasts on Fosun International stock, see the HK:0656 Stock Forecast page.

More about Fosun International

Fosun International is a diversified Chinese conglomerate with core businesses spanning health, happiness, wealth and intelligent manufacturing, with particular strength in pharmaceuticals and insurance. The group has a significant overseas footprint, with more than half of its 2025 revenue generated outside China, and positions itself as a leaner, innovation‑driven player in key growth sectors.

YTD Price Performance: -5.71%

Average Trading Volume: 24,001,776

Technical Sentiment Signal: Sell

Current Market Cap: HK$33.65B

For detailed information about 0656 stock, go to TipRanks’ Stock Analysis page.